Vitamin D and stroke: Promise for prevention and better outcome

Current Vascular Pharmacology

Volumn 12, Issue 1, 2014, Pages 117-124

  Makariou, Stefania E ^a   Michel, Patrik ^b   Tzoufi, Meropi S ^a   Challa, Anna ^a   Milionis, Haralampos J ^a,b  

^a UNIVERSITY OF IOANNINA   (Greece)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Antiatherogenic effect; Antithrombotic effect; Cardiovascular disease; Deficiency; Neuroprotection; Stroke; Vitamin D

Indexed keywords

ANTICOAGULANT AGENT; ATORVASTATIN; CALCIUM; CALCIUM ION; GAMMA GLUTAMYLTRANSFERASE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUTATHIONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDUCIBLE NITRIC OXIDE SYNTHASE; LIPOPOLYSACCHARIDE; NEUROTROPHIC FACTOR; TRANSFORMING GROWTH FACTOR BETA1; VITAMIN D; VITAMIN D RECEPTOR;

ANGIOCARDIOGRAPHY; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CAROTID ATHEROSCLEROSIS; CENTRAL NERVOUS SYSTEM; CEREBROVASCULAR ACCIDENT; DIET SUPPLEMENTATION; DIETARY INTAKE; DISEASE ASSOCIATION; GENE EXPRESSION; HEART INFARCTION; HUMAN; HYPOXIC ISCHEMIC ENCEPHALOPATHY; ISCHEMIC HEART DISEASE; META ANALYSIS (TOPIC); NEUROPROTECTION; NONHUMAN; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW (TOPIC); VITAMIN D DEFICIENCY;

COGNITION; FIBRINOLYTIC AGENTS; HUMANS; NEUROPROTECTIVE AGENTS; RISK FACTORS; STROKE; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84897387670     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/15701611113119990119     Document Type: Article

References (95)

1. Brown RD, Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO. Stroke incidence, prevalence, and survival: secular trends in Rochester, Minnesota, through 1989. Stroke 1996; 27: 373-80.
2. Menotti A, Jacobs DR, Blackburn H, et al. Twenty-fiveyear prediction of stroke deaths in the seven countries study: the role of blood pressure and its changes. Stroke 1996; 27: 381-7.
3. Peterlik M, Cross HS. Vitamin D and calcium deficits predispose for multiple chronic diseases. Eur J Clin Invest 2005; 35: 290-304.
4. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357: 266-81.
5. Nadir MA, Szwejkowski BR, Witham MD. Vitamin D and cardiovascular prevention. Cardiovasc Ther 2010; 28: e5-12.
6. Melamed ML, Michos ED, Post W, Astor B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med 2008; 168: 1629-37.
7. Makariou S, Liberopoulos EN, Elisaf M, Challa A. Novel roles of vitamin D in disease: what is new in 2011? Eur J Intern Med 2011; 22: 355-62.
8. Poole KE, Loveridge N, Barker PJ, et al. Reduced vitamin D in acute stroke. Stroke 2006; 37: 243-5.
9. Scragg R, Sowers M, Bell C. Serum 25-hydroxyvitamin D, ethnicity, and blood pressure in the Third National Health and Nutrition Examination Survey. Am J Hypertens 2007; 20: 713-9.
10. Wang TJ, Pencina MJ, Booth SL, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008; 117: 503-11.
11. Dobnig H, Pilz S, Scharnagl H, et al. Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. Arch Intern Med 2008; 168: 1340-9.
12. Pilz S, Tomaschitz A, Drechsler C, Zittermann A, Dekker JM, Marz W. Vitamin D supplementation: a promising approach for the prevention and treatment of strokes. Curr Drug Targets 2011; 12: 88-96.
13. Anderson JL, May HT, Horne BD, et al. Relation of vitamin D deficiency to cardiovascular risk factors, disease status, and incident events in a general healthcare population. Am J Cardiol 2010; 106: 963-8.
14. Kilkkinen A, Knekt P, Aro A, et al. Vitamin D status and the risk of cardiovascular disease death. Am J Epidemiol 2009; 170: 1032-9.
15. Drechsler C, Pilz S, Obermayer-Pietsch B, et al. Vitamin D deficiency is associated with sudden cardiac death, combined cardiovascular events, and mortality in haemodialysis patients. Eur Heart J 2010; 31: 2253-61.
16. Pilz S, Dobnig H, Fischer JE, et al. Low vitamin d levels predict stroke in patients referred to coronary angiography. Stroke 2008; 39: 2611-3.
17. Sato Y, Kaji M, Metoki N, Satoh K, Iwamoto J. Does compensatory hyperparathyroidism predispose to ischemic stroke? Neurology 2003; 60: 626-9.
18. Karagiannis A, Tziomalos K, Mikhailidis DP, et al. Seasonal variation in the occurrence of stroke in Northern Greece: a 10 year study in 8204 patients. Neurol Res 2010; 32: 326-31.
19. Souberbielle JC, Body JJ, Lappe JM, et al. Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: Recommendations for clinical practice. Autoimmun Rev 2010; 9: 709-15.
20. Sato Y, Iwamoto J, Kanoko T, Satoh K. Low-dose vitamin D prevents muscular atrophy and reduces falls and hip fractures in women after stroke: a randomized controlled trial. Cerebrovasc Dis 2005; 20: 187-92.
21. Pilz S, Tomaschitz A, Drechsler C, Zittermann A, Dekker JM, März W. Vitamin D supplementation: a promising approach for the prevention and treatment of strokes. Curr Drug Targets 2011; 12: 88-96.
22. Thomas MK, Lloyd-Jones DM, Thadhani RI, et al. Hypovitaminosis D in medical inpatients. N Engl J Med 1998; 338: 777-83.
23. Sato Y. Abnormal bone and calcium metabolism in patients after stroke. Arch Phys Med Rehabil 2000; 81: 117-21.
24. Aihara K, Azuma H, Akaike M, et al. Disruption of nuclear vitamin D receptor gene causes enhanced thrombogenicity in mice. J Biol Chem 2004; 279: 35798-802.
25. Kiraly SJ, Kiraly MA, Hawe RD, Makhani N. Vitamin D as a neuroactive substance: review. ScientificWorldJournal 2006; 6: 125-39.
26. Marniemi J, Alanen E, Impivaara O, et al. Dietary and serum vitamins and minerals as predictors of myocardial infarction and stroke in elderly subjects. Nutr Metab Cardiovasc Dis 2005; 15: 188-97.
27. Reis JP, von Muhlen D, Michos ED, et al. Serum vitamin D, parathyroid hormone levels, and carotid atherosclerosis. Atherosclerosis 2009; 207: 585-90.
28. Carrelli AL, Walker MD, Lowe H, et al. Vitamin D deficiency is associated with subclinical carotid atherosclerosis: the Northern Manhattan study. Stroke 2011; 42: 2240-5.
29. Michos ED, Reis JP, Post WS, et al. 25-Hydroxyvitamin D deficiency is associated with fatal stroke among whites but not blacks: The NHANES-III linked mortality files. Nutrition 2012; 28: 367-71.
30. Brewer LC, Michos ED, Reis JP. Vitamin D in atherosclerosis, vascular disease, and endothelial function. Curr Drug Targets 2010; 12: 54-60.
31. Kent ST. The use of ground and satellite data to determine the relationship between long and short-term sunlight exposure with stroke incidence in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. International Stroke Conference 2012; Abstract 2591.
32. Judd SE. Vitamin D intake: A novel neuroprotectant. International Stroke Conference 2012; Abstract 2212.
33. Soni M, Kos K, Lang IA, Jones K, Melzer D, Llewellyn DJ. Vitamin D and cognitive function. Scand J Clin Lab Invest Suppl 2012; 243: 79-82.
34. Dickens AP, Lang IA, Langa KM, Kos K, Llewellyn DJ. Vitamin D, cognitive dysfunction and dementia in older adults. CNS Drugs 2011; 25: 629-39.
35. Wang L, Manson JE, Sesso HD. Calcium intake and risk of cardiovascular disease: a review of prospective studies and randomized clinical trials. Am J Cardiovasc Drugs 2012; 12: 105-16.
36. Sun Q, Pan A, Hu FB, Manson JE, Rexrode KM. 25-hydroxyvitamin D levels and the risk of stroke: a prospective study and meta-analysis. Stroke 2012 [epub ahead of print].
37. Sun Q, Shi L, Rimm EB, et al. Vitamin D intake and risk of cardiovascular disease in US men and women. Am J Clin Nutr 2011; 94: 534-42.
38. Bostick RM, Kushi LH, Wu Y, Meyer KA, Sellers TA, Folsom AR. Relation of calcium, vitamin D, and dairy food intake to ischemic heart disease mortality among postmenopausal women. Am J Epidemiol 1999; 149: 151-61.
39. Hsia J, Heiss G, Ren H, et al. Calcium/vitamin D supplementation and cardiovascular events. Circulation 2007; 115: 846-54.
40. LaCroix AZ, Kotchen J, Anderson G, et al. Calcium plus vitamin D supplementation and mortality in postmenopausal women: the Women's Health Initiative calcium-vitamin D randomized controlled trial. J Gerontol A Biol Sci Med Sci 2009; 64: 559-67.
41. Elamin MB, Abu Elnour NO, Elamin KB, et al. Vitamin D and cardiovascular outcomes: a systematic review and meta-analysis. J Clin Endocrinol Metab 2011; 96: 1931-42.
42. Grandi NC, Breitling LP, Brenner H. Vitamin D and cardiovascular disease: systematic review and meta-analysis of prospective studies. Prev Med 2010; 51: 228-33.
43. Sutherland MK, Wong L, Somerville MJ, et al. Reduction of calbindin-28k mRNA levels in Alzheimer as compared to Huntington hippocampus. Brain Res Mol Brain Res 1993; 18: 32-42.
44. Haussler MR, Haussler CA, Jurutka PW, et al. The vitamin D hormone and its nuclear receptor: molecular actions and disease states. J Endocrinol 1997; 154 (Suppl): S57-73.
45. Melcangi RC, Panzica G. Steroids in the nervous system: a Pandora's box? Trends Neurosci 2001; 24: 311-2.
46. Florentin M, Elisaf MS, Mikhailidis DP, Liberopoulos EN. Vitamin D and metabolic syndrome: is there a link? Curr Pharm Des 2010; 16: 3417-34.
47. Garcion E, Wion-Barbot N, Montero-Menei CN, Berger F, Wion D. New clues about vitamin D functions in the nervous system. Trends Endocrinol Metab 2002; 13: 100-5.
48. Garcion E, Thanh XD, Bled F, et al. 1,25-Dihydroxyvitamin D3 regulates gamma 1 transpeptidase activity in rat brain. Neurosci Lett 1996; 216: 183-6.
49. Garcion E, Sindji L, Leblondel G, Brachet P, Darcy F. 1,25-dihydroxyvitamin D3 regulates the synthesis of gamma-glutamyl transpeptidase and glutathione levels in rat primary astrocytes. J Neurochem 1999; 73: 859-66.
50. McGrath J, Feron F, Eyles D, Mackay-Sim A. Vitamin D: the neglected neurosteroid? Trends Neurosci 2001; 24: 570-2.
51. Raiten DJ, Picciano MF. Vitamin D and health in the 21st century: bone and beyond. Executive summary. Am J Clin Nutr 2004; 80: 1673S-7S.
52. Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr 2004; 80: 1678S-88S.
53. Wang Y, Chiang YH, Su TP, et al. Vitamin D(3) attenuates cortical infarction induced by middle cerebral arterial ligation in rats. Neuropharmacology 2000; 39: 873-80.
54. Abe K, Hayashi T. Expression of the glial cell line-derived neurotrophic factor gene in rat brain after transient MCA occlusion. Brain Res 1997; 776: 230-4.
55. Wang Y, Lin SZ, Chiou AL, Williams LR, Hoffer BJ. Glial cell line-derived neurotrophic factor protects against ischemia-induced injury in the cerebral cortex. J Neurosci 1997; 17: 4341-8.
56. Lin SZ, Chiou AL, Wang Y. Ketamine antagonizes nitric oxide release from cerebral cortex after middle cerebral artery ligation in rats. Stroke 1996; 27: 747-52.
57. Garcion E, Nataf S, Berod A, Darcy F, Brachet P. 1,25-Dihydroxyvitamin D3 inhibits the expression of inducible nitric oxide synthase in rat central nervous system during experimental allergic encephalomyelitis. Mol Brain Res 1997; 45: 255-67.
58. Brewer LD, Thibault V, Chen KC, Langub MC, Landfield PW, Porter NM. Vitamin D hormone confers neuroprotection in parallel with downregulation of L-type calcium channel expression in hippocampal neurons. J Neurosci 2001; 21: 98-108.
59. Veenstra TD, Prufer K, Koenigsberger C, Brimijoin SW, Grande JP, Kumar R. 1,25-Dihydroxyvitamin D3 receptors in the central nervous system of the rat embryo. Brain Res 1998; 804: 193-205.
60. Prufer K, Veenstra TD, Jirikowski GF, Kumar R. Distribution of 1,25-dihydroxyvitamin D3 receptor immunoreactivity in the rat brain and spinal cord. J Chem Neuroanat 1999; 16: 135-45.
61. Nicotera P, Orrenius S. The role of calcium in apoptosis. Cell Calcium 1998;23:173-80.
62. Toescu EC. Apoptosis and cell death in neuronal cells: where does Ca2+ fit in? Cell Calcium 1998; 24: 387-403.
63. Witham MD, Dove FJ, Sugden JA, Doney AS, Struthers AD. The effect of vitamin D replacement on markers of vascular health in stroke patients-A randomised controlled trial. Nutr Metab Cardiovasc Dis 2010; doi: 10.1016/ j.numecd.2010.11.001.
64. Widlansky ME, Gokce N, Keaney JF, Vita JA. The clinical implications of endothelial dysfunction. J Am Coll Cardiol 2003; 42: 1149e60.
65. Reddy Vanga S, Good M, Howard PA, Vacek JL. Role of vitamin D in cardiovascular health. Am J Cardiol 2010; 106: 798-805.
66. Sato Y, Kaji M, Oizumi K. Vitamin D deficiency and the risk of hip fractures among disabled elderly stroke patients. Stroke 2001; 32: 1673-7.
67. Lamb SE, Ferrucci L, Volapto S, Fried LP, Guralnik JM. Risk factors for falling in homedwelling older women with stroke: the Women's Health and Aging Study. Stroke 2003; 34: 494-501.
68. Pasco JA, Henry MJ, Kotowicz MA, et al. Seasonal periodicity of serum vitamin D and parathyroid hormone, bone resorption, and fractures: the Geelong Osteoporosis Study. J Bone Miner Res 2004; 19: 752-8.
69. Kanis J, Oden A, Johnell O. Acute and long-term increase in fracture risk after hospitalization for stroke. Stroke 2001; 32: 702-6.
70. Browner WS, Pressman AR, Nevitt MC, Cauley JA, Cummings SR. Association between low bone density and stroke in elderly women. The study of osteoporotic fractures. Stroke 1993; 24: 940-6.
71. Sato Y, Kaji M, Honda Y, et al. Abnormal calcium homeostasis in disabled stroke patients with low 25-hydroxyvitamin D. Bone 2004; 34: 710-5.
72. Perez-Castrillon JL, Vega G, Abad L, et al. Effects of atorvastatin on vitamin D levels in patients with acute ischemic heart disease. Am J Cardiol 2007; 99: 903-5.
73. Wilczek H, Sobra J, Justova V, et al. Iatropathogenic effect of Mevacor on vitamin D metabolism. Cas Lek Cesk 1989; 128: 1254-6.
74. Wilczek H, Sobra J, Ceska R, et al. Monitoring plasma levels of vitamin D metabolites in simvastatin (Zocor) therapy in patients with familial hypercholesterolemia. Cas Lek Cesk 1994; 133: 727-9.
75. Yavuz B, Ertugrul DT, Cil H, et al. Increased levels of 25 hydroxyvitamin D and 1,25-dihydroxyvitamin D after rosuvastatin treatment: a novel pleiotropic effect of statins? Cardiovasc Drugs Ther 2009; 23: 295-9.
76. Ertugrul DT, Yavuz B, Cil H, et al. STATIN-D Study: Comparison of the influences of rosuvastatin and fluvastatin treatment on the levels of 25 hydroxyvitamin D. Cardiovasc Ther 2011; 29: 146-52.
77. Makariou SE, Liberopoulos EN, Agouridis AP, Challa A, Elisaf M. Effect of rosuvastatin monotherapy and in combination with fenofibrate or omega-3 fatty acids on serum vitamin D levels. J Cardiovasc Pharmacol Ther [published online 19 March 2012 DOI: 101177/1074248412439470].
78. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004; 109: III39-43.
79. Lee P, Greenfield JR. 25-Hydroxyvitamin D and risk of stroke: possible mediation by statin therapy? Stroke 2009; 40: e35.
80. Wilding PM. Cardiovascular disease, statins and vitamin D. Br J Nurs 2012; 21: 214-20.
81. Glueck CJ, Budhani SB, Masineni SS, et al. Vitamin D deficiency, myositis-myalgia, and reversible statin intolerance. Curr Med Res Opin 2011; 27: 1683-90.
82. Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Vitamin D deficiency, statin-related myopathy and other links with vascular risk. Curr Med Res Opin 2011; 27: 1691-2.
83. Amarenco P, Bogousslavsky J, Callahan Ar, et al. Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators (2006) High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355: 549-59.
84. Mascitelli L, Pezzetta F, Goldstein MR. Statin therapy in the secondary prevention of cerebrovascular events: is it really beneficial in clinical practice? Med Hypotheses 2010; 74: 398.
85. Goldstein LB, Amarenco P, Lamonte M, et al. Relative effects of statin therapy on stroke and cardiovascular events in men and women: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study. Stroke 2008; 39: 2444-8.
86. Chaturvedi S, Zivin J, Breazna A, et al. Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack. Neurology 2009; 72: 688-94.
87. Amarenco P, Benavente O, Goldstein LB, et al. Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial by stroke subtypes. Stroke 2009; 40: 1405-9.
88. Sillesen H, Amarenco P, Hennerici MG, et al. Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke 2008; 39: 3297-302.
89. Callahan A, Amarenco P, Goldstein LB, et al. Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Arch Neurol 2011; 68: 1245-51.
90. Mascitelli L, Goldstein MR, Grant WB. Stroke prevention: might vitamin D be safer than statins? Intern Emerg Med 2011;DOI 10.1007/s11739-011-0652-1.
91. Guessous I, Bochud M, Bonny O, Burnier M. Calcium, vitamin D and cardiovascular disease. Kidney Blood Press Res 2011; 34: 404-17.
92. Wang X, Qin X, Demirtas H, et al. Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet 2007; 369: 1876-82.
93. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 23-33.
94. Lonn E, Yusuf S, Arnold MJ, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006; 354: 1567-77.
95. Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004; 291: 565-75.